Knopp Biosciences was featured as both the cover story, detailing the company’s recent hypereosinophilic syndrome (HES) trial, as well as in a key editorial entitled “Dexpramipexole: a new antieosinophil drug?” in the August 2, 2018 edition of Blood.
The editorial, by world eosinophilic disease expert Dr. Gerald J. Gleich of the University of Utah School of Medicine, terms dexpramipexole “very promising,” noting that “the results in patients with durable and sustained responses are impressive and suggest that dexpramipexole could be an effective treatment of patients with eosinophil-related diseases.”
Taken together, results from the HES trial and a separate Phase 2 trial of dexpramipexole in chronic rhinosinusitis with nasal polyps “set the stage for Phase 3 clinical trials in patients with common eosinophil-related diseases,” the editorial says. Observing that long-term glucocorticoid therapy and associated adverse effects remain the mainstay of treatment in eosinophil-associated diseases, the editorial notes, “These early results encourage belief that this drug could herald a welcome change.”
A full copy of the Blood editorial is available at http://www.bloodjournal.org/content/132/5/461
Comments are closed.